Does the administration of meloxicam before head and neck radiotherapy reduce the risk of mandibular osteoradionecrosis? An animal model study

Yamasaki, Mayra Cristina; Roque‐Torres, Gina Delia; Peroni, Leonardo Vieira; Nascimento, Eduarda Helena Leandro; Salmon, Benjamin; Oliveira, Matheus Lima; Freitas, Deborah Queiroz; Correr-Sobrinho, Lourenço

doi:10.1007/s00784-020-03701-x

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meloxicam can be used as a radioprotector in the mandible of irradiated rats. In addition, a single dose of meloxicam administered 1 h after a lethal radiation dose can achieve an increased survival rate of 30 days; however, it has been reported to be ineffective to administer meloxicam 24 h after lethal exposure ( 75 ). Intercellular adhesion molecule-1 (ICAM-1) and COX-2 are known factors involved in causing myocardial infarction after radiation exposure and were previously reported to be elevated after radiation exposure ( 77 ).…”

Section: Strategies To Reduce Radiation Injurymentioning

confidence: 99%

“…Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2), with anti-proliferative and anti-angiogenetic effects, and is beneficial in alleviating gastrointestinal toxicity and improving radiation tolerability (74)(75)(76). Meloxicam can be used as a radioprotector in the mandible of irradiated rats.…”

Section: Carbamazepine (Cbz)mentioning

confidence: 99%

See 1 more Smart Citation

Radioprotective countermeasures for radiation injury (Review)

Liu

Liang

et al. 2023

Mol Med Rep

View full text Add to dashboard Cite

A series of physiological and pathological changes occur after radiotherapy and accidental exposure to ionizing radiation (IR). These changes cause serious damage to human tissues and can lead to death. Radioprotective countermeasures are radioprotective agents that prevent and reduce IR injury or have therapeutic effects. Based on a good understanding of radiobiology, a number of protective agents have achieved positive results in early clinical trials. The present review grouped known radioprotective agents according to biochemical categories and potential clinical use, and reviewed radiation countermeasures, i.e., radioprotectors, radiation mitigators and radiotherapeutic agents, with an emphasis on their current status and research progress. The aim of the present review is to facilitate the selection and application of suitable radioprotectors for clinicians and researchers, to prevent or reduce IR injury.

show abstract

Section: Strategies To Reduce Radiation Injurymentioning

confidence: 99%

Section: Carbamazepine (Cbz)mentioning

confidence: 99%